Silexion Therapeutics Corp (NASDAQ:SLXN) is Wildcat Capital Management LLC’s 8th Largest Position

Wildcat Capital Management LLC lessened its holdings in shares of Silexion Therapeutics Corp (NASDAQ:SLXN) by 88.9% during the fourth quarter, HoldingsChannel reports. The firm owned 113,428 shares of the company’s stock after selling 907,424 shares during the quarter. Silexion Therapeutics accounts for approximately 0.1% of Wildcat Capital Management LLC’s investment portfolio, making the stock its 8th largest holding. Wildcat Capital Management LLC owned 0.07% of Silexion Therapeutics worth $228,000 as of its most recent SEC filing.

Silexion Therapeutics Stock Performance

Shares of SLXN stock opened at $1.35 on Thursday. The business’s 50-day moving average is $1.99. Silexion Therapeutics Corp has a 1-year low of $0.58 and a 1-year high of $41.85.

Analyst Ratings Changes

Separately, Maxim Group initiated coverage on Silexion Therapeutics in a research note on Friday, November 1st. They issued a “buy” rating and a $9.00 target price for the company.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.